109 related articles for article (PubMed ID: 27035336)
1. Coupling Gd‑DTPA with a bispecific, recombinant protein anti‑EGFR‑iRGD complex improves tumor targeting in MRI.
Xin X; Sha H; Shen J; Zhang B; Zhu B; Liu B
Oncol Rep; 2016 Jun; 35(6):3227-35. PubMed ID: 27035336
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium-conjugated PLA-PEG nanoparticles as liver targeted molecular MRI contrast agent.
Chen Z; Yu D; Liu C; Yang X; Zhang N; Ma C; Song J; Lu Z
J Drug Target; 2011 Sep; 19(8):657-65. PubMed ID: 21091273
[TBL] [Abstract][Full Text] [Related]
3. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent.
Han L; Li J; Huang S; Huang R; Liu S; Hu X; Yi P; Shan D; Wang X; Lei H; Jiang C
Biomaterials; 2011 Apr; 32(11):2989-98. PubMed ID: 21277017
[TBL] [Abstract][Full Text] [Related]
4. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy.
Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B
J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823
[TBL] [Abstract][Full Text] [Related]
5. Tumor‑penetrating peptide fused EGFR single‑domain antibody enhances radiation responses following EGFR inhibition in gastric cancer.
Ji F; Sha H; Meng F; Zhu A; Ding N; Zhang H; Xu H; Qian H; Yu L; Liu Q; Liu B
Oncol Rep; 2018 Sep; 40(3):1583-1591. PubMed ID: 29956805
[TBL] [Abstract][Full Text] [Related]
6. [Gadolinium-loaded nanoparticle as a novel molecular imaging contrast agent for magnetic resonance imaging].
Liu LZ; Guo GJ; Zeng MS; Lü YC; Liu XW; Cui CY; Wu PH; Li L
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(4):240-3. PubMed ID: 17425867
[TBL] [Abstract][Full Text] [Related]
7. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
8. The synthesis of a D-glucosamine contrast agent, Gd-DTPA-DG, and its application in cancer molecular imaging with MRI.
Zhang W; Chen Y; Guo DJ; Huang ZW; Cai L; He L
Eur J Radiol; 2011 Sep; 79(3):369-74. PubMed ID: 21106316
[TBL] [Abstract][Full Text] [Related]
9. Interstitial fluid pressure and associated lymph node metastasis revealed in tumors by dynamic contrast-enhanced MRI.
Hompland T; Ellingsen C; Øvrebø KM; Rofstad EK
Cancer Res; 2012 Oct; 72(19):4899-908. PubMed ID: 23027087
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the interstitial fluid pressure of tumors by dynamic contrast-enhanced magnetic resonance imaging with contrast agents of different molecular weights.
Hompland T; Gulliksrud K; Ellingsen C; Rofstad EK
Acta Oncol; 2013 Apr; 52(3):627-35. PubMed ID: 23126523
[TBL] [Abstract][Full Text] [Related]
11. Hydrothermally synthesized PEGylated calcium phosphate nanoparticles incorporating Gd-DTPA for contrast enhanced MRI diagnosis of solid tumors.
Mi P; Kokuryo D; Cabral H; Kumagai M; Nomoto T; Aoki I; Terada Y; Kishimura A; Nishiyama N; Kataoka K
J Control Release; 2014 Jan; 174():63-71. PubMed ID: 24211705
[TBL] [Abstract][Full Text] [Related]
12. Gadolinium-chitosan nanoparticles as a novel contrast agent for potential use in clinical bowel-targeted MRI: a feasibility study in healthy rats.
Cheng JJ; Zhu J; Liu XS; He DN; Xu JR; Wu LM; Zhou J; Feng Q
Acta Radiol; 2012 Oct; 53(8):900-7. PubMed ID: 22919051
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts.
Ovrebø KM; Ellingsen C; Galappathi K; Rofstad EK
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e121-7. PubMed ID: 22381901
[TBL] [Abstract][Full Text] [Related]
14. Assessment of tumor radioresponsiveness and metastatic potential by dynamic contrast-enhanced magnetic resonance imaging.
Øvrebø KM; Gulliksrud K; Mathiesen B; Rofstad EK
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):255-61. PubMed ID: 21816291
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis.
Cho HJ; Yoon HY; Koo H; Ko SH; Shim JS; Cho JH; Park JH; Kim K; Kwon IC; Kim DD
J Control Release; 2012 Aug; 162(1):111-8. PubMed ID: 22709587
[TBL] [Abstract][Full Text] [Related]
16. [Gd(DTPA-BDMA)] as a magnetic resonance contrast agent: acute toxicity test and preliminary images.
Sheu RS; Wang YM; Kuo YT; Cheng TH; Jaw TS; Liu GC
Kaohsiung J Med Sci; 2002 Feb; 18(2):77-83. PubMed ID: 12056172
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced (DCE) MRI assessment of microvascular characteristics in the murine orthotopic pancreatic cancer model.
Wu L; Lv P; Zhang H; Fu C; Yao X; Wang C; Zeng M; Li Y; Wang X
Magn Reson Imaging; 2015 Jul; 33(6):737-60. PubMed ID: 25169584
[TBL] [Abstract][Full Text] [Related]
18. Fabrication and evaluation of tumor-targeted positive MRI contrast agent based on ultrasmall MnO nanoparticles.
Huang H; Yue T; Xu K; Golzarian J; Yu J; Huang J
Colloids Surf B Biointerfaces; 2015 Jul; 131():148-54. PubMed ID: 25982318
[TBL] [Abstract][Full Text] [Related]
19. Kinetic analysis of hyaluronidase activity using a bioactive MRI contrast agent.
Shiftan L; Neeman M
Contrast Media Mol Imaging; 2006; 1(3):106-12. PubMed ID: 17193686
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive magnetic resonance imaging of transport and interstitial fluid pressure in ectopic human lung tumors.
Hassid Y; Furman-Haran E; Margalit R; Eilam R; Degani H
Cancer Res; 2006 Apr; 66(8):4159-66. PubMed ID: 16618737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
